Drug Profile
Research programme: cancer vaccines - Vaxenta
Alternative Names: Placental vaccination therapy - Vaxenta; XenUvaXLatest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Vaxenta Biotechnologies
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Malignant melanoma
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route)
- 27 Mar 2023 Discontinued - Preclinical for Malignant melanoma in USA (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Colorectal-cancer in USA